ADVA
15.12.2020 09:02:11 CET | Business Wire | Press release
ADVA (FSE: ADV) today launched a unique set of edge and access network synchronization devices with enhanced capabilities for next-generation applications such as 5G. The latest Oscilloquartz solutions address key challenges for a wide range of industries by bringing new levels of timing accuracy and resilience to edge networks. The OSA 5412 and 5422 offer precise phase, frequency and time-of-day synchronization and can be used for time-as-a-service applications. For the first time, communication service providers, enterprises, broadcast networks and power utilities can deploy synchronization technology at the edge that features multi-band GNSS receivers for nanosecond accuracy. The OSA 5412 and 5422 utilize in-service sync probing and assurance as well as innovative GNSS assurance capabilities. The products also provide support for eight field-upgradeable 10Gbit/s ports, ensuring the scale and efficiency needed for next-generation smart grids, industrial IoT applications and 5G connectivity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201215005081/en/
“Our latest solutions build on the great success we’ve had with our access synchronization product line. Now operators can harness the power of multi-band GNSS receivers to deliver highly accurate, UTC-traceable timing at the network edge. That enables the availability and precision that will be essential for tomorrow’s services,” said Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “By extending the feature set of our edge technology, we’re empowering CSPs to smoothly transition to the reliability and accuracy required for 5G and, at the same time, enabling our unique innovation to be used across a wide range of verticals. With support for 10Gbit/s and 1Gbit/s interfaces as well as hardware timestamping, our access timing products are the ultimate in future-proof, space-efficient synchronization.”
The OSA 5412 is a highly flexible access network synchronization solution that offers compact and cost-effective timing distribution and assurance. The OSA 5422 is engineered for the most extreme conditions. It meets stringent frequency and phase synchronization requirements, delivers the best holdover performance of any edge device on the market, and supports multiple legacy interfaces such BITS and IRIG. Both solutions address new ITU-T specifications, including for class A and B PRTCs, ePRTCs with strict holdover requirements, and the newly improved class C and D boundary clocks. They also feature onboard multi-band, multi-constellation GNSS receivers that overcome ionospheric delay variation far more cost-efficiently than rival solutions using high-end rubidium oscillators. The OSA 5412 and 5422 support multiple PTP profiles, NTP and SyncE with the highest number of 1/10GbE ports on the market. What’s more, both devices are engineered with optional OLED display and with hot-swappable modules and power supplies to be easily upgraded in the field.
“Access grandmaster clocks need to meet stricter demands for accuracy and reliability than ever before, and many industries have their own specific set of stringent timing requirements. That’s why we’ve evolved our portfolio of edge and access network synchronization solutions for the specific challenges of the 5G era,” commented Gil Biran, general manager, Oscilloquartz, ADVA. “Our OSA 5412 and 5422 answer the most urgent timing needs of mission-critical infrastructure in multiple verticals. They provide nanosecond precision, an abundance of fan-out interface options and operational simplicity thanks to the management and monitoring capabilities of our Ensemble Controller with Sync Director. Operators of broadcast, healthcare, financial networks and more now have a straightforward and affordable path from legacy to next-generation timing.”
Further information on the OSA 5412 and 5422 is available in these slides: https://adva.li/osa-5412-5422-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20201215005081/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom